Compare NEOG & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEOG | WVE |
|---|---|---|
| Founded | 1981 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 1995 | 2015 |
| Metric | NEOG | WVE |
|---|---|---|
| Price | $11.22 | $13.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | $10.67 | ★ $30.44 |
| AVG Volume (30 Days) | ★ 2.6M | 2.2M |
| Earning Date | 04-10-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $894,661,000.00 | $3,704,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.67 | $15.93 |
| P/E Ratio | $124.89 | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $3.87 | $5.28 |
| 52 Week High | $11.43 | $21.73 |
| Indicator | NEOG | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 68.60 | 50.01 |
| Support Level | $10.37 | $12.53 |
| Resistance Level | N/A | $14.56 |
| Average True Range (ATR) | 0.35 | 0.77 |
| MACD | -0.06 | 0.19 |
| Stochastic Oscillator | 80.03 | 40.20 |
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.